Praxis Precision Medicines Inc Stock News

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on August 1, 2025, the Compensation Committee of Praxis' Board of Directors g...

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Pip...

Investors can contact the law firm at no cost to learn more about recovering their losses

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Tru...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants a - Corporate Participant Marcio Silva De'Souza - President, CEO & Director Steven Petrou - Co-Founder & Chief Scientific Officer Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division Brian Peter Skorney - Robert W. Baird & Co. Incorporated...

Praxis (PRAX) Q2 Loss Widens 90%

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days

The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)